Nonclinical Safety Profile of Revusiran, a 1st-Generation GalNAc-siRNA Conjugate for Treatment of Hereditary Transthyretin-Mediated Amyloidosis.
Nucleic Acid Ther. 2020 Feb;30(1):33-49. doi: 10.1089/nat.2019.0796. Epub 2019 Dec 10.
Nucleic Acid Ther. 2020.
PMID: 31821125
Free PMC article.